Globeflex Capital L P Takes Position in AngioDynamics, Inc. $ANGO

Key Points

• Globeflex Capital acquired 104,155 AngioDynamics shares in the second quarter, worth approximately $1.36 million and representing about 0.25% of the company. Institutional investors and hedge funds collectively own 89.43% of ANGO.
• Analyst views remain mixed: HC Wainwright and Canaccord raised their price targets and issued “buy” ratings, while Zacks Research downgraded the stock to “strong sell.” The overall consensus is “Hold,” with an average price target of $19.50.
• AngioDynamics exceeded quarterly expectations, reporting an adjusted loss of $0.07 per share versus the $0.11 consensus loss and revenue of $86.61 million versus estimates of $80.24 million. The stock opened at $15.77, near its 52-week high of $16.29.

Globeflex Capital L P bought a new position in AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 104,155 shares of the medical instruments supplier's stock, valued at approximately $1,355,000. Globeflex Capital L P owned approximately 0.25% of AngioDynamics as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in ANGO. BlackRock Inc. bought a new stake in AngioDynamics in the second quarter valued at $49,480,000. Kotler Kevin bought a new position in shares of AngioDynamics in the fourth quarter valued at $21,997,000. Weber Capital Management LLC ADV bought a new position in AngioDynamics in the 4th quarter valued at about $17,978,000. UBS Group AG boosted its position in shares of AngioDynamics by 83.6% during the third quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier's stock valued at $12,315,000 after buying an additional 501,881 shares during the last quarter. Finally, Millennium Management LLC boosted its holdings in AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier's stock worth $20,030,000 after acquiring an additional 393,682 shares during the last quarter. 89.43% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at AngioDynamics

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the business's stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president directly owned 64,745 shares of the company's stock, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 6.00% of the company's stock.

Analysts Set New Price Targets

ANGO has been the topic of several research analyst reports. HC Wainwright boosted their price objective on AngioDynamics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Wednesday, July 15th. Canaccord Genuity Group increased their price objective on AngioDynamics from $16.00 to $20.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Zacks Research downgraded AngioDynamics from a "hold" rating to a "strong sell" rating in a research report on Thursday, July 16th. Wall Street Zen upgraded AngioDynamics from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of AngioDynamics in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $19.50.

AngioDynamics Stock Performance

Shares of ANGO stock opened at $15.77 on Tuesday. The company has a market capitalization of $651.81 million, a PE ratio of -18.13 and a beta of 0.33. AngioDynamics, Inc. has a 52-week low of $9.39 and a 52-week high of $16.29. The business's fifty day moving average is $14.03 and its 200 day moving average is $12.10.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.04. The company had revenue of $86.61 million during the quarter, compared to analyst estimates of $80.24 million. AngioDynamics had a negative return on equity of 5.73% and a negative net margin of 11.48%.AngioDynamics has set its FY 2027 guidance at -0.290--0.240 EPS. On average, sell-side analysts forecast that AngioDynamics, Inc. will post -0.25 EPS for the current fiscal year.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics, Inc. (NASDAQ:ANGO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source